BC Innovations | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
BC Week In Review | Nov 16, 2018
Company News

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
BC Extra | Nov 15, 2018
Company News

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on...
BC Innovations | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BC Extra | Jun 29, 2018
Preclinical News

Inhibiting REST in hair cells to reduce hearing loss

In a Cell paper , a University of Iowa and NIH team showed that an inactive form of RE1-silencing transcription factor (REST; NRSF) is necessary for hearing and suggested that inhibiting REST in hair cells with...
BioCentury | May 18, 2018
Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Innovations | Oct 26, 2017
Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
BC Innovations | Mar 2, 2017
Translation in Brief

PISA’s epigenetic tilt

Italian researchers have developed a platform for creating intracellular antibodies that selectively target acetylated versions of proteins without affecting their unmodified forms. The team believes the method can be modified to target proteins bearing other...
BC Week In Review | Aug 8, 2016
Clinical News

Pracinostat regulatory update

FDA granted breakthrough therapy designation to MEI’s pracinostat in combination with azacitidine to treat acute myelogenous leukemia (AML) in patients ages >=75 or who are otherwise unfit for intensive chemotherapy. Pracinostat is an oral inhibitor...
Items per page:
1 - 10 of 41